Table 2.
Demographic and clinical data of all subjects.
| Characteristics (Mean ± S.E.) | Controls (n = 80) | SVR (n = 86/160, 53.7%) | NR (n = 74/160, 46.3%) |
|---|---|---|---|
| Age, (years) Range, (min–max) |
39.85 ± 6.61 (19.00–53.00) |
41.17 ± 6.91d (20.00–53.00) |
39.08 ± 6.94d (20.00–54.00) |
| Gender | |||
| Females, n (%) | 36 (45%) | 44 (51.2%)d | 38 (51.4%)d |
| Males, n (%) | 44 (55%) | 42 (48.8%)d | 36 (48.6%)d |
| BMI, (kg/m2) | 24.30 ± 6.26 | 25.20 ± 5.24d | 26.04 ± 6.53d |
| ALT, (IU/L), A | 30.40 ± 0.94 | 60.00 ± 2.54a∗ | 54.00 ± 3.47b∗ |
| ALT, (IU/L), B | – | 33.73 ± 2.83 | 41.88 ± 4.17c∗ |
| AST, (IU/L), A | 32.12 ± 1.19 | 62.13 ± 2.61a∗ | 60.35 ± 3.85b∗,d |
| AST, (IU/L), B | – | 34.26 ± 1.19 | 65.11 ± 4.39c∗ |
| Total Bilirubin, (mg/dL), A | 0.78 ± 0.03 | 1.05 ± 0.08a∗ | 1.15 ± 0.04b∗,d |
| Total Bilirubin, (mg/dL), B | – | 0.78 ± 0.01 | 1.22 ± 0.1c |
| Direct Bilirubin, (mg/dL), A | 0.15 ± 0.01 | 0.24 ± 0.02a∗ | 0.26 ± 0.03b∗,d |
| Direct Bilirubin, (mg/dL), B | – | 0.14 ± 0.01 | 0.31 ± 0.04c∗ |
| Albumin, (g/dL), A | 4.34 ± 0.13 | 3.86 ± 0.04a | 3.77 ± 0.1b∗,d |
| Albumin, (g/dL), B | – | 3.28 ± 0.02 | 3.90 ± 0.07c∗ |
| AFP, (U/L), A | 4.11 ± 0.19 | 5.77 ± 0.37a | 6.02 ± 0.41b∗,b |
| AFP, (U/L), B | – | 4.64 ± 0.29 | 5.34 ± 0.46b |
S.E.: standard error.
n: size of samples.
A: before treatment.
B: after treatment.
a/a*: a significant/a high significant correlation (χ2 > 3.84) when comparing responders with controls.
b/b*: a significant/a high significant correlation (χ2 > 3.84) when comparing non-responders with controls.
c/c*: a significant/a high significant correlation (χ2 > 3.84) when comparing non-responders with responders.
d: a non-significant correlation (χ2 < 3.84) either when comparing non-responders or responders with controls.